Literature DB >> 19493955

Ultrasound molecular imaging of atherosclerosis.

Beat A Kaufmann1.   

Abstract

Recent advances in our understanding of the pathophysiological mechanisms of atherosclerosis have created the need for better non-invasive imaging of vascular phenotype. Ultrasound is widely available, inexpensive, and well suited for high-throughput screening in populations that are at risk for atherosclerosis. Novel ultrasonic approaches for the diagnosis of vascular changes in atherosclerosis include (1) assessment of plaque composition by evaluation of the backscattering properties of tissue, (2) assessment of the changes in arterial wall biomechanics, (3) assessment of plaque neovascularization, and (4) molecular imaging of vascular phenotype changes on a subcellular level. It is thought that such new imaging methodologies will lead to earlier detection of atherosclerosis, and better assessment of the risk for aggressive disease progression. Novel therapies for atherosclerosis will undoubtedly become available within the next decades, and non-invasive imaging techniques will be needed for cost-efficient application of existing and new drugs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19493955     DOI: 10.1093/cvr/cvp179

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  13 in total

1.  Molecular imaging of vasa vasorum neovascularization via DEspR-targeted contrast-enhanced ultrasound micro-imaging in transgenic atherosclerosis rat model.

Authors:  Julius L Decano; Anne Marie Moran; Nelson Ruiz-Opazo; Victoria L M Herrera
Journal:  Mol Imaging Biol       Date:  2011-12       Impact factor: 3.488

Review 2.  Intravascular imaging of vulnerable coronary plaque: current and future concepts.

Authors:  Rishi Puri; Matthew I Worthley; Stephen J Nicholls
Journal:  Nat Rev Cardiol       Date:  2011-01-25       Impact factor: 32.419

3.  Factors affecting the endothelial retention of targeted microbubbles: influence of microbubble shell design and cell surface projection of the endothelial target molecule.

Authors:  Elham Khanicheh; Martina Mitterhuber; Katharina Kinslechner; Lifen Xu; Jonathan R Lindner; Beat A Kaufmann
Journal:  J Am Soc Echocardiogr       Date:  2012-01-23       Impact factor: 5.251

4.  Ultrasonic imaging of endothelial CD81 expression using CD81-targeted contrast agents in in vitro and in vivo studies.

Authors:  Fei Yan; Xiang Li; Qiaofeng Jin; Juanjuan Chen; Robin Shandas; Junru Wu; Lu Li; Tao Ling; Wei Yang; Yun Chen; Xin Liu; Hairong Zheng
Journal:  Ultrasound Med Biol       Date:  2012-02-16       Impact factor: 2.998

5.  Translating Molecular Imaging of the Vulnerable Plaque-a Vulnerable Project?

Authors:  Gezim Bala; Alexis Broisat; Tony Lahoutte; Sophie Hernot
Journal:  Mol Imaging Biol       Date:  2018-06       Impact factor: 3.488

Review 6.  Molecular ultrasound imaging: current status and future directions.

Authors:  N Deshpande; A Needles; J K Willmann
Journal:  Clin Radiol       Date:  2010-07       Impact factor: 2.350

Review 7.  Molecular imaging: current status and emerging strategies.

Authors:  M A Pysz; S S Gambhir; J K Willmann
Journal:  Clin Radiol       Date:  2010-07       Impact factor: 2.350

8.  Antiangiogenic cancer therapy: monitoring with molecular US and a clinically translatable contrast agent (BR55).

Authors:  Marybeth A Pysz; Kira Foygel; Jarrett Rosenberg; Sanjiv S Gambhir; Michel Schneider; Jürgen K Willmann
Journal:  Radiology       Date:  2010-06-01       Impact factor: 11.105

9.  An animal model allowing controlled receptor expression for molecular ultrasound imaging.

Authors:  Reshu Saini; Anna G Sorace; Jason M Warram; Marshall J Mahoney; Kurt R Zinn; Kenneth Hoyt
Journal:  Ultrasound Med Biol       Date:  2012-11-02       Impact factor: 2.998

Review 10.  Antibody-based imaging strategies for cancer.

Authors:  Jason M Warram; Esther de Boer; Anna G Sorace; Thomas K Chung; Hyunki Kim; Rick G Pleijhuis; Gooitzen M van Dam; Eben L Rosenthal
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.